The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma has reported that their RNAi therapeutic candidate, imdusiran, combined with a short course of interferon, has achieved a functional ...
In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Precision BioSciences (DTIL – Research Report), with a price target of $2.50. Soumit Roy’s Buy rating for Precision ...
The Journal of the American Medical Association (JAMA) stated on March 10 that between 1.6 million and 2.4 million Americans live with chronic hepatitis B virus (CHBV). New recommendations released ...
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS), a key player in advancing treatments for chronic hepatitis B (cHBV), outlined its progress in Q1 2025, showcasing pivotal clinical ...
WARMINSTER, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive ...
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results